https://www.ibcomms.agency/releases23/cellprothera-advances-towards-its-phase-iii-clinical-trials-with-the-development-of-a-new-potency-assay 2024-01-30 https://www.ibcomms.agency/releases23/biosenic-wishes-to-issue-a-correction-in-its-funding-release%2C-issued-december-6. 2024-01-30 https://www.ibcomms.agency/releases23/terumo-blood-and-cell-technologies-takes-part-in-connecting-the-dots%3A-a-new-film-series-showcasing-the-pivotal-role-of-medical-technologies-to-improve-healthcare 2024-01-30 https://www.ibcomms.agency/releases23/biosenic-on-its-way-to-find-the-necessary-funds-to-perform-its-key-clinical-trial-on-chronic-graft-versus-host-disease 2024-01-30 https://www.ibcomms.agency/releases23/cellprothera-expanding-into-ischemic-stroke-following-publication-of-positive-preclinical-results-with-its-cd34%2B-stem-cell-platform%C2%A0 2023-12-05 https://www.ibcomms.agency/releases23/biosenic-provides-third-quarter-2023-business-update 2023-11-27 https://www.ibcomms.agency/releases23/trakcel-appoints-dr.-akshay-peer-as%C2%A0senior-vice-president-product-at-trakcel 2023-11-27 https://www.ibcomms.agency/releases23/exmoor-completes-expansion-into-full-service-cell-and-gene-therapy-cdmo-partner-with-opening-of-gmp-facilities 2023-11-27 https://www.ibcomms.agency/releases23/exmoor-appoints-matthew-paterson-as-first-chief-commercial-officer 2023-11-27 https://www.ibcomms.agency/releases23/minoryx-announces-enrollment-of-first-patients-with-cerebral-adrenoleukodystrophy-(cald)-in-us-phase-3-clinical-trial%2C-calyx 2023-11-27 https://www.ibcomms.agency/releases23/organabio-launches-decentralized-support-division-for-vaccine-and-cell-and-gene-therapy-clinical-trials 2023-10-10 https://www.ibcomms.agency/releases23/terumo-blood-and-cell-technologies-launches-study-with-biocentriq(r)-to-generate-public-car-t-cell-data-using-terumo-bct%E2%80%99s-cgt-manufacturing-platforms 2023-10-05 https://www.ibcomms.agency/releases23/information-on-the-total-number-of-voting-rights-and-shares-10%2F23 2023-10-10 https://www.ibcomms.agency/releases23/ctmc-partners-with-scaleready-to-automate%2C-close%2C-and-scale-for-greater-patient-accessibility 2023-10-04 https://www.ibcomms.agency/releases23/immutep-announces-abstract-accepted-for-presentation-at-the-society-for-immunotherapy-of-cancer-(sitc)-2023-annual-meeting 2023-10-04 https://www.ibcomms.agency/releases23/commercial-manufacturing-of-eftilagimod-alpha-at-2000l-scale-granted-authorization-for-clinical-trial-use 2023-09-21 https://www.ibcomms.agency/releases23/terumo-blood-and-cell-technologies-collaborates-with-mcq-to-enable-automated-gas-mixing-for-expansion-of-cell-and-gene-therapies 2023-09-21 https://www.ibcomms.agency/releases23/cellprothera-completes-enrollment-in-phase-i%2Fiib-trial-for-post-myocardial-infarction-cell-therapy%C2%A0%C2%A0 2023-10-05 https://www.ibcomms.agency/releases23/terumo-blood-and-cell-technologies-appoints-jackie-kunzler-to-head-research-and-development 2023-09-19 https://www.ibcomms.agency/releases23/biosenic-publishes-new-evidence-of-beneficial-effects-of-arsenic-trioxide-treatment-supporting-clinical-trial-for-systemic-sclerosis 2023-09-19 https://www.ibcomms.agency/releases23/biosenic-reports-half-year-2023-results 2023-10-05 https://www.ibcomms.agency/releases23/terumo-blood-and-cell-technologies'-peer-reviewed-publication-shows-hollow-fiber-based-bioreactors-can-produce-8x-viral-vector-producing-cells-in-four-days 2023-09-12 https://www.ibcomms.agency/releases23/cell-and-gene-therapy-industry-pioneer-%26-gmp-expert%2C-gerhard-bauer%2C-joins-orgenesis-business%2C-octomera%2C-to-drive-continued-expansion-of-pocare-facilities-and-service-support 2023-09-12 https://www.ibcomms.agency/releases23/information-on-the-total-number-of-voting-rights-and-shares 2023-09-12 https://www.ibcomms.agency/releases23/biosenic-receives-a-chinese-patent-with-broad-claims%2C-protecting-the-combined-use-of-metal-ions-and-arsenic-salts-to-treat-a-wide-range-of-serious-diseases 2023-09-12 https://www.ibcomms.agency/releases23/exmoor-pharma-and-kincell-bio-partner-to-offer-full-service-development-and-manufacturing-capabilities-for-global-cgt-clients 2023-09-12 https://www.ibcomms.agency/releases23/orgenesis-provides-business-update-for-second-quarter-of-2023 2023-09-12 https://www.ibcomms.agency/releases23/terumo-blood-and-cell-technologies%E2%80%99-reveos(r)-automated-whole-blood-processing-system-cleared-by-fda-for-us-commercial-use. 2023-09-12 https://www.ibcomms.agency/releases23/immutep-receives-positive-scientific-advice-from-european-medicines-agency 2023-09-12 https://www.ibcomms.agency/releases23/immutep-quarterly-activities-report-%26-appendix-4c-q4-fy23 2023-09-12 https://www.ibcomms.agency/releases23/first-patient-dosed-in-chemotherapy-free-triple-combination-phase-ii-trial-targeting-soft-tissue-sarcoma 2023-09-12 https://www.ibcomms.agency/releases23/orgenesis-announces-name-change-of-morgenesis-business-unit-to-octomera.-name-change-and-rebranding-reflects-progression-of-the-business-and-focus-on-changing-the-paradigm-of-cgt-production 2023-09-12 https://www.ibcomms.agency/releases23/uk-immersive-technology-company-to-create-mixed-reality-training-platform-for-biopharmaceutical-and-healthcare-sectors 2023-09-12 https://www.ibcomms.agency/releases23/biosenic-provides-financial-update 2023-09-12 https://www.ibcomms.agency/releases23/biosenic-provides-financial-update.-launch-of-negotiation-with-main-creditors.-agreement-with-global-tech-opportunities-(gto)-to-secure-short-term-financing%C2%A0 2023-09-12 https://www.ibcomms.agency/releases23/immutep-completes-aud-80-million-capital-raise 2023-09-12 https://www.ibcomms.agency/releases23/immutep-granted-united-states-patent-for-imp761%2C-a-first-in-class-agonist-antibody-targeting-lag-3 2023-09-12 https://www.ibcomms.agency/releases23/biosenic-presents-data-on-its-new-copper-arsenic-trioxide-combination-for-immunological-disorders-at-the-25th-international-conference-on-redox-medicine 2023-09-12 https://www.ibcomms.agency/releases23/biosenic-puts-phase-iib-allob-trial-on-hold. 2023-09-12 https://www.ibcomms.agency/releases23/sctbio-and-cyto-care-collaborate-to-improve-cell-therapy-cryopreservation-and-logistics-capabilities-in-europe 2023-09-12 https://www.ibcomms.agency/releases23/orgenesis-and-university-of-california%2C-davis-sign-partnership-agreement-for-rollout-of-cell-and-gene-therapy-mobile-processing-units-and-labs-throughout-california 2023-09-12 https://www.ibcomms.agency/releases23/immutep-reports-final-positive-data-in-second-line-head-and-neck-squamous-cell-carcinoma-at-asco-2023-annual-meeting 2023-09-12 https://www.ibcomms.agency/releases23/information-on-the-total-number-of-voting-rights-and-shares 2023-09-12